Targeting BM PDX by the complex I inhibitor IACS-010759, significantly reduced tumour growth in the majority of ER + BM PDX, including multiple endocrine-resistant models and PDX established from patients progressing on palbociclib. The gene discussed is ESR1; the disease is neoplasm.